Pasithea Therapeutics Corp., a biotechnology company focused on the discovery, research and development of treatments for central nervous system (CNS) disorders, has acquired AlloMek Therapeutics LLC, a privately-held biotechnology company.

Allomek’s therapeutic candidate, CIP-137401, is a macrocyclic mitogen-activated protein kinase kinase 1/2 (MEK) inhibitor used in CNS-related applications, including neurofibromatosis type 1 and Noonan syndrome, as well as Allomek’s multiple sclerosis development program.

“The acquisition of AlloMek represents the successful continuation of our business development strategy,” comments Tiago Reis Marques, chief executive officer of Pasithea. “Expanding our CNS-focused drug development pipeline with near-term clinical opportunities addressing rare RASopathies positions us for long-term growth opportunities and potential synergies with our existing tolerizing program, which we believe will yield the greatest results for patients, the healthcare community and stockholders.”